StoneX Group’s Relmada Therapeutics RLMD Stock Holding History

StoneX Group’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,234	Closed	-$3.57K	–	990
2025 Q1	$3.57K	Buy	+13,234	New	+$4.39K	﹤0.01%	836

Other funds holding RLMD

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

StoneX Group's RLMD Position: Q2 2025 in Review

StoneX Group sold out of Relmada Therapeutics (RLMD) in Q2 2025, closing a stake of 13,234 shares — an estimated $3.57K sold.

StoneX Group first reported a position in RLMD in Q1 2025 and held it in 1 quarter. The position peaked at $3.57K in Q1 2025. 50 funds tracked by Wall St. Rank hold RLMD as of Q2 2025.

StoneX Group reported no remaining Relmada Therapeutics position as of Q2 2025 after selling out during the quarter.
StoneX Group sold 13,234 Relmada Therapeutics shares in Q2 2025, an estimated $3.57K.
StoneX Group first reported a position in Relmada Therapeutics in Q1 2025 and held it in 1 quarter.
StoneX Group's Relmada Therapeutics position peaked at $3.57K in Q1 2025.
50 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2025.

Based on StoneX Group's 13F filing for Q2 2025, filed 13 Aug 2025.